Regeneron Pharmaceuticals, Inc. (REGN) Shares Sold by State Street Corp
State Street Corp reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,290,303 shares of the biopharmaceutical company’s stock after selling 89,848 shares during the quarter. State Street Corp owned approximately 3.10% of Regeneron Pharmaceuticals worth $1,615,987,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of REGN. FMR LLC grew its position in shares of Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after buying an additional 416,192 shares during the period. BlackRock Inc. grew its position in shares of Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock worth $3,039,305,000 after buying an additional 41,406 shares during the period. Wellington Management Group LLP grew its position in shares of Regeneron Pharmaceuticals by 7.9% in the 1st quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares during the period. Vanguard Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 2.9% in the 2nd quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock worth $2,588,533,000 after buying an additional 148,962 shares during the period. Finally, Artisan Partners Limited Partnership grew its position in shares of Regeneron Pharmaceuticals by 1.5% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock worth $963,852,000 after buying an additional 29,252 shares during the period. 67.95% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-shares-sold-by-state-street-corp/1613033.html.
In other news, Chairman P Roy Vagelos sold 10,986 shares of the stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $470.17, for a total transaction of $5,165,287.62. Following the completion of the transaction, the chairman now directly owns 329,543 shares in the company, valued at approximately $154,941,232.31. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Robert E. Landry sold 526 shares of the stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total value of $248,371.94. Following the transaction, the senior vice president now owns 9,099 shares of the company’s stock, valued at $4,296,456.81. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 89,468 shares of company stock valued at $42,312,448. 10.80% of the stock is owned by company insiders.
REGN has been the topic of a number of recent research reports. Leerink Swann reaffirmed an “outperform” rating and issued a $493.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, June 13th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 14th. Piper Jaffray Companies upped their target price on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 20th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $421.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 21st. Finally, Canaccord Genuity set a $484.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 20th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $489.92.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down 0.02% during mid-day trading on Friday, reaching $463.30. The company had a trading volume of 242,365 shares. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The stock’s 50-day moving average price is $460.15 and its 200 day moving average price is $451.28. The company has a market capitalization of $49.13 billion, a PE ratio of 46.48 and a beta of 1.62.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm’s quarterly revenue was up 21.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.82 EPS. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.93 EPS for the current year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.